Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
NCT04949828 · View on ClinicalTrials.gov ↗
Study Summary
Exocrine Pancreatic Insufficiency (EPI) is a condition where pancreatic enzyme quantity or activity is reduced below threshold needed for normal digestion. Symptoms include bloating, flatulence, diarrhea and steatorrhea. This is an observational study assessing for effect of CREON on symptoms of EPI in participants with EPI due to chronic pancreatitis.
Conditions Studied
Interventions
- DRUG CREON
Study Locations (6)
California
- Stanford University School of Med /ID# 229530 — Stanford
Florida
- University of Florida - Archer /ID# 227057 — Gainesville
Maryland
- John Hopkins University /ID# 227061 — Baltimore
New York
- NYU Langone Health /ID# 230818 — New York
Ohio
- The Ohio State University Wexner Medical Center /ID# 227844 — Columbus
Texas
- Baylor College of Medicine - Baylor Medical Center /ID# 227067 — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2024-02-29 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04949828
The ClinicalTrials.gov registry entry for NCT04949828 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 603 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Chronic Pancreatitis appearing as the primary indexed condition, and to 1 intervention — of which CREON is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04949828 reports 6 study locations spanning 6 distinct geographic areas — top geographies include California, Florida, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04949828 about?
NCT04949828 is a clinical study titled "Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms". Exocrine Pancreatic Insufficiency (EPI) is a condition where pancreatic enzyme quantity or activity is reduced below threshold needed for normal digestion. Symptoms include bloating, flatulence, diarrhea and steatorrhea. This is an observational study assessing for effect of CREON on symptoms of EPI...
What is the current status of trial NCT04949828?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2021-09-16. Estimated completion is 2024-02-29.
What conditions does trial NCT04949828 study?
This clinical trial studies the following conditions: Chronic Pancreatitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04949828?
The interventions under investigation include: CREON (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04949828?
This trial is sponsored by AbbVie, which has 603 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04949828 being conducted?
This trial has 6 study locations across California, Florida, Maryland, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.